Page last updated: 2024-12-11

N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide : A tripeptide resulting from the formal condensation of the carboxy group of N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valine with the amino group of benzyl (2E,4S)-4-(L-leucylamino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate. It is an inhibitor of the main protease of SARS-CoV-2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6323191
CHEMBL ID1230135
CHEBI ID147376
CHEBI ID39900
SCHEMBL ID23948035

Synonyms (26)

Synonym
CHEMBL1230135
benzyl (e,4s)-4-[[(2s)-4-methyl-2-[[(2s)-3-methyl-2-[[(2s)-2-[(5-methylisoxazole-3-carbonyl)amino]propanoyl]amino]butanoyl]amino]pentanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate
DB04595
(e)-(4s,6s)-8-methyl-6-((s)-3-methyl-2-{(s)-2-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionylamino}-butyrylamino)-5-oxo-4-((r)-2-oxo-pyrrolidin-3-ylmethyl)-non-2-enoic acid benzyl ester
n3
benzyl (e,4s)-4-[[(2s)-4-methyl-2-[[(2s)-3-methyl-2-[[(2s)-2-[(5-methyl-1,2-oxazole-3-carbonyl)amino]propanoyl]amino]butanoyl]amino]pentanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate
n-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-l-alanyl-l-valyl-n-{(2s,3e)-5-(benzyloxy)-5-oxo-1-[(3r)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-l-leucinamide
CHEBI:147376
the n3 compound
Q27095335
inhibitor n3
n-(5-methyl-1,2-oxazole-3-carbonyl)-l-alanyl-l-valyl-n-{(2s,3e)-5-(benzyloxy)-5-oxo-1-[(3s)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-l-leucinamide
n-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-l-alanyl-l-valyl-n-{(2s,3e)-5-(benzyloxy)-5-oxo-1-[(3s)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-l-leucinamide
CHEBI:39900
(3s,6s,9s,12s,e)-benzyl 9-isobutyl-6-isopropyl-3-methyl-1-(5-methylisoxazol-3-yl)-1,4,7,10-tetraoxo-12-(((s)-2-oxopyrrolidin-3-yl)methyl)-2,5,8,11-tetraazapentadec-13-en-15-oate
884650-98-0
bdbm512688
acs.jmedchem.1c00409_st.282
bdbm419120
SCHEMBL23948035
mpro inhibitor n3
HY-136149
CS-0120008
BN178815
AKOS040756262
Z5371961820
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiviral agentA substance that destroys or inhibits replication of viruses.
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitorAn EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69).
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
isoxazolesOxazoles in which the N and O atoms are adjacent.
pyrrolidin-2-onesA pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
benzyl ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)9.00000.00403.43889.5100AID1805532
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)9.00000.00402.92669.9600AID1805532
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusKi5.45000.00753.00839.1100AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)67.00000.00022.45859.9600AID1803933; AID1805532
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2Ki6.63330.00001.63079.0000AID1805801; AID1881679
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)16.77000.00304.11059.8200AID1803934
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1718084Inhibition of HcoV-EMC 3C-like protease2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1881679Binding affinity to SARS CoV-2 main protease pH41A mutant expressed in Escherichia coli BL21 DE3 cells using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as substrate by fluorescence based analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1881680Inhibition of MERS CoV 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as substrate by fluorescence based analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1881681Antiviral activity against SARS CoV-2 infected in African green monkey Vero cells assessed as inhibition of plaque formation by viral plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1718114Inhibition of 3C-like protease in SARS-CoV2 infected in African green monkey vero cells assessed as antiviral activity incubated for 1 hr by crystal violet staining based plaque reduction assay2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1881683Antiviral activity against FIPV infected in African green monkey Vero cells assessed as inhibition of plaque formation by viral plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1881684Antiviral activity against MHV-A59 infected in African green monkey Vero cells assessed as inhibition of plaque formation by viral plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1718115Inhibition of SARS-CoV N-terminal (GS residues)-fused wild type 3C-like protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 s substrate by fluorescence method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1881686Cytotoxicity against African green monkey Vero cells2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1718116Inhibition of SARS-CoV C-terminal (GPH6 residues)-fused wild type 3C-like protease expressed in Escherichia coli BL21(DE3) cells using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 s substrate by fluorescence method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1685583Antiviral activity against SARS CoV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis2021RSC medicinal chemistry, Jan-01, Volume: 12, Issue:1
Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M
AID1884554Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) using Mca-AVLQSGFRK(Dnp)K as substrate by double reciprocal plot analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
AID1884558Antiviral activity against SARS COV-2 infected in vero cells assessed as inhibition of viral replication measured after 72 hrs by RT-qPCR method2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
AID1881685Antiviral activity against MHV infected in African green monkey Vero cells assessed as inhibition of plaque formation by viral plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1881682Antiviral activity against HCoV-229E infected in African green monkey Vero cells assessed as inhibition of plaque formation by viral plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1491360Inhibition of SARS coronavirus Mpro using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH as substrate by fluorescence assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
AID1718117Inhibition of SARS-CoV wild type 3C-like protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 s substrate by fluorescence method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1803934Antiviral activity assay from Article 10.1038/s41586-020-2223-y: \\Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors \\2020Nature, 06, Volume: 582, Issue:7811
Structure of M
AID1805532Various Assay from Article 10.1002/cmdc.202100576: \\A patent review on SARS coronavirus main protease (3CLpro) inhibitors.\\2022ChemMedChem, 01-05, Volume: 17, Issue:1
A Patent Review on SARS Coronavirus Main Protease (3CL
AID1803933high-throughput activity assay from Article 10.1038/s41586-020-2223-y: \\Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors \\2020Nature, 06, Volume: 582, Issue:7811
Structure of M
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's7 (87.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.76 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (37.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]